Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (August 15, 2020): 112250. https://doi.org/10.1016/j.bios.2020.112250.

PMID
32392161
Full Text

Zhang, Tian, Joyce K. Hwang, Daniel J. George, and Sumanta K. Pal. “The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.” Cancer Treat Res Commun 24 (June 12, 2020): 100183. https://doi.org/10.1016/j.ctarc.2020.100183.

PMID
32563923
Full Text

Shore, Neal D., Fred Saad, Michael S. Cookson, Daniel J. George, Daniel R. Saltzstein, Ronald Tutrone, Hideyuki Akaza, et al. “Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.” N Engl J Med 382, no. 23 (June 4, 2020): 2187–96. https://doi.org/10.1056/NEJMoa2004325.

PMID
32469183
Full Text

Bakthavatsalam, Subha, Petpailin Wiangnak, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.” Bioorg Med Chem Lett 30, no. 11 (June 1, 2020): 127148. https://doi.org/10.1016/j.bmcl.2020.127148.

PMID
32253061
Full Text

Shore, Neal, Celestia S. Higano, Daniel J. George, Cora N. Sternberg, Fred Saad, Bertrand Tombal, Kurt Miller, et al. “Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis, May 13, 2020. https://doi.org/10.1038/s41391-020-0236-0.

PMID
32404868
Full Text

Ramaswamy, Krishnan, Stanislav Lechpammer, Jack Mardekian, Ahong Huang, Neil M. Schultz, Rickard Sandin, Li Wang, Onur Baser, and Daniel J. George. “Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.” Adv Ther 37, no. 5 (May 2020): 2083–97. https://doi.org/10.1007/s12325-020-01260-x.

PMID
32112280
Full Text

Markham, Merry Jennifer, Kerri Wachter, Neeraj Agarwal, Monica M. Bertagnolli, Susan Marina Chang, William Dale, Catherine S. M. Diefenbach, et al. “Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.” J Clin Oncol 38, no. 10 (April 1, 2020): 1081. https://doi.org/10.1200/JCO.19.03141.

PMID
32013670
Full Text

Gupta, Santosh, Daniel H. Hovelson, Gabor Kemeny, Susan Halabi, Wen-Chi Foo, Monika Anand, Jason A. Somarelli, et al. “Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.” Genes Chromosomes Cancer 59, no. 4 (April 2020): 225–39. https://doi.org/10.1002/gcc.22824.

PMID
31705765
Full Text

George, Daniel J., Susan Halabi, Patrick Healy, Darius Jonasch, Monika Anand, Julia Rasmussen, Sarah Y. Wood, Charles Spritzer, John F. Madden, and Andrew J. Armstrong. “Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.” Urol Oncol 38, no. 3 (March 2020): 79.e15-79.e22. https://doi.org/10.1016/j.urolonc.2019.08.015.

PMID
31522863
Full Text

Labriola, Matthew Kyle, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, Eric F. Kong, James R. White, et al. “Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.” J Immunother Cancer 8, no. 1 (March 2020). https://doi.org/10.1136/jitc-2019-000319.

PMID
32221016
Full Text

Pages